Review article: Antitumoural immunity in colorectal cancer - Current and potential future implications in clinical practice

Alimentary Pharmacology and Therapeutics

Volumn 38, Issue 1, 2013, Pages 3-15

  Koudougou, C ^a   Bonneville, M ^b   Matysiak Budnik, T ^a   Touchefeu, Y ^a  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b Groupe Cytokines et Récepteurs   (France)

Author keywords

[No Author keywords available]

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; AZATHIOPRINE; CARCINOEMBRYONIC ANTIGEN; CD45RO ANTIGEN; CETUXIMAB; CHORIONIC GONADOTROPIN BETA SUBUNIT; DACARBAZINE; DENDRITIC CELL VACCINE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2; IPILIMUMAB; OXALIPLATIN; PLACEBO; SIPULEUCEL T; TRANSCRIPTION FACTOR FOXP3; TUMOR CELL VACCINE;

ADENOMATOUS POLYP; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CASTRATION RESISTANT PROSTATE CANCER; CD8+ T LYMPHOCYTE; COLORECTAL ADENOMA; COLORECTAL CANCER; DISEASE FREE SURVIVAL; ENTERITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPROMISED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOSURVEILLANCE; LATENT VIRUS INFECTION; LIVER TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MELANOMA; MEMORY T LYMPHOCYTE; METASTASIS FREE SURVIVAL; METASTATIC COLORECTAL CANCER; MICROSATELLITE INSTABILITY; NONHODGKIN LYMPHOMA; ORGAN TRANSPLANTATION; OVERALL SURVIVAL; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; REGULATORY T LYMPHOCYTE; REVIEW; SKIN CANCER; SURVIVAL RATE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY;

ANTICARCINOGENIC AGENTS; ANTIGENS, NEOPLASM; COLORECTAL NEOPLASMS; HUMANS; IMMUNE SYSTEM; IMMUNITY; IMMUNOCOMPROMISED HOST; IMMUNOTHERAPY; PROGNOSIS;

EID: 84878795964     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12337     Document Type: Review

References (88)

1. Parkin DM, Bray F, Ferlay J, Pisani P,. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Hanahan D, Weinberg RA,. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74.
3. Qian BZ, Pollard JW,. Macrophage diversity enhances tumor progression and metastasis. Cell 2010; 141: 39-51.
4. DeNardo DG, Andreu P, Coussens LM,. Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity. Cancer Metastasis Rev 2010; 29: 309-16.
5. Grivennikov SI, Greten FR, Karin M,. Immunity, inflammation, and cancer. Cell 2010; 140: 883-99.
6. Dunn GP, Old LJ, Schreiber RD,. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004; 21: 137-48.
7. Hayakawa Y,. Targeting NKG2D in tumor surveillance. Expert Opin Ther Targets 2012; 16: 587-99.
8. Rachagani S, Torres MP, Moniaux N, Batra SK,. Current status of mucins in the diagnosis and therapy of cancer. BioFactors 2009; 35: 509-27.
9. Zhang K, Sikut R, Hansson GC,. A MUC1 mucin secreted from a colon carcinoma cell line inhibits target cell lysis by natural killer cells. Cell Immunol 1997; 176: 158-65.
10. Leach DR, Krummel MF, Allison JP,. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996; 271: 1734-6.
11. Hodi FS, O'Day SJ, McDermott DF, et al,. Improved survival with ipilimumab in patients with metastatic melanoma. N Eng J Med 2010; 363: 711-23.
12. Robert C, Thomas L, Bondarenko I, et al,. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Eng J Med 2011; 364: 2517-26.
13. Ohtani H,. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human colorectal cancer. Cancer Immun 2007; 7: 4.
14. Engels EA, Biggar RJ, Hall HI, et al,. Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer 2008; 123: 187-94.
15. Watkins C, Sahni R, Holla N, Litchfield J, Youngberg G, Krishnaswamy G,. Malignancy in common variable immune deficiency: report of two rare cases of gastrointestinal malignancy and a review of the literature. Cardiovasc Hematol Disord Drug Targets 2012; 12: 21-7.
16. Kinlen LJ, Sheil AG, Peto J, Doll R,. Collaborative United Kingdom-Australasian study of cancer in patients treated with immunosuppressive drugs. Br Med J 1979; 2: 1461-6.
17. Caillard S, Lelong C, Pessione F, Moulin B,. Post-transplant lymphoproliferative disorders occurring after renal transplantation in adults: report of 230 cases from the French Registry. Am J Transplant 2006; 6: 2735-42.
18. Kremers WK, Devarbhavi HC, Wiesner RH, Krom RA, Macon WR, Habermann TM,. Post-transplant lymphoproliferative disorders following liver transplantation: incidence, risk factors and survival. Am J Transplant 2006; 6: 1017-24.
19. Beaugerie L, Brousse N, Bouvier AM, et al,. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009; 374: 1617-25.
20. Nguyen T, Vacek PM, O'Neill P, Colletti RB, Finette BA,. Mutagenicity and potential carcinogenicity of thiopurine treatment in patients with inflammatory bowel disease. Cancer Res 2009; 69: 7004-12.
21. Spier BJ, Walker AJ, Cornett DD, Pfau PR, Halberg RB, Said A,. Screening colonoscopy and detection of neoplasia in asymptomatic, average-risk, solid organ transplant recipients: case-control study. Transplant Int 2010; 23: 1233-8.
22. Haagsma EB, Hagens VE, Schaapveld M, et al,. Increased cancer risk after liver transplantation: a population-based study. J Hepatol 2001; 34: 84-91.
23. Jiang Y, Villeneuve PJ, Fenton SS, Schaubel DE, Lilly L, Mao Y,. Liver transplantation and subsequent risk of cancer: findings from a Canadian cohort study. Liver Transpl 2008; 14: 1588-97.
24. Johnson EE, Leverson GE, Pirsch JD, Heise CP,. A 30-year analysis of colorectal adenocarcinoma in transplant recipients and proposal for altered screening. J Gastrointest Surg 2007; 11: 272-9.
25. Sanchez EQ, Marubashi S, Jung G, et al,. De novo tumors after liver transplantation: a single-institution experience. Liver Transpl 2002; 8: 285-91.
26. Sint Nicolaas J, de Jonge V, Steyerberg EW, Kuipers EJ, van Leerdam ME, Veldhuyzen-van Zanten SJ,. Risk of colorectal carcinoma in post-liver transplant patients: a systematic review and meta-analysis. Am J Transplant 2010; 10: 868-76.
27. Parikshak M, Pawlak SE, Eggenberger JC, Lee CS, Szilagy EJ, Margolin DA,. The role of endoscopic colon surveillance in the transplant population. Dis Colon Rectum 2002; 45: 1655-60.
28. Rudraraju M, Osowo AT, Singh V, Carey EJ,. Do patients need more frequent colonoscopic surveillance after liver transplantation? Transplant Proc 2008; 40: 1522-4.
29. Koornstra JJ, Wesseling J, de Jong AE, Vasen HF, Kleibeuker JH, Haagsma EB,. Increased risk of colorectal neoplasia in asymptomatic liver-transplant recipients. Gut 2007; 56: 892-3.
30. Park HY, Chang BJ, Lim SW, et al,. Risk of colorectal neoplasia in patients with solid organ transplantation. Clin Transplant 2012; 26: 50-6.
31. Atassi T, Thuluvath PJ,. Risk of colorectal adenoma in liver transplant recipients compared to immunocompetent control population undergoing routine screening colonoscopy. J Clin Gastrolenterol 2003; 37: 72-3.
32. Papaconstantinou HT, Sklow B, Hanaway MJ, et al,. Characteristics and survival patterns of solid organ transplant patients developing de novo colon and rectal cancer. Dis Colon Rectum 2004; 47: 1898-903.
33. Buell JF, Papaconstantinou HT, Skalow B, Hanaway MJ, Alloway RR, Woodle ES,. De novo colorectal cancer: five-year survival is markedly lower in transplant recipients compared with the general population. Transplant Proc 2005; 37: 960-1.
34. Khoury W, Lavery IC, Kiran RP,. Effects of chronic immunosuppression on long-term oncologic outcomes for colorectal cancer patients undergoing surgery. Ann Surg 2011; 253: 323-7.
35. Lindstrom L, Lapidus A, Ost A, Bergquist A,. Increased risk of colorectal cancer and dysplasia in patients with Crohn's colitis and primary sclerosing cholangitis. Dis Colon Rectum 2011; 54: 1392-7.
36. Vera A, Gunson BK, Ussatoff V, et al,. Colorectal cancer in patients with inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis. Transplantation 2003; 75: 1983-8.
37. Hanouneh IA, Macaron C, Lopez R, Zein NN, Lashner BA,. Risk of colonic neoplasia after liver transplantation for primary sclerosing cholangitis. Inflamm Bowel Dis 2012; 18: 269-74.
38. Torres J, Pineton de Chambrun G, Itzkowitz S, Sachar DB, Colombel JF,. Review article: colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease. Aliment Pharmacol Ther 2011; 34: 497-508.
39. Cunningham D, Atkin W, Lenz HJ, et al,. Colorectal cancer. Lancet 2010; 375: 1030-47.
40. Sargent DJ, Marsoni S, Monges G, et al,. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 2010; 28: 3219-26.
41. Pages F, Berger A, Camus M, et al,. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Eng J Med 2005; 353: 2654-66.
42. Nosho K, Baba Y, Tanaka N, et al,. Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J Pathol 2010; 222: 350-66.
43. Salama P, Phillips M, Grieu F, et al,. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol 2009; 27: 186-92.
44. deLeeuw RJ, Kost SE, Kakal JA, Nelson BH,. The prognostic value of FoxP3+ tumor-infiltrating lymphocytes in cancer: a critical review of the literature. Clin Cancer Res 2012; 18: 3022-9.
45. Ladoire S, Martin F, Ghiringhelli F,. Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer. Cancer Immunol Immunother 2011; 60: 909-18.
46. Tosolini M, Kirilovsky A, Mlecnik B, et al,. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res 2011; 71: 1263-71.
47. Galon J, Costes A, Sanchez-Cabo F, et al,. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313: 1960-4.
48. Pages F, Kirilovsky A, Mlecnik B, et al,. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol 2009; 27: 5944-51.
49. Mlecnik B, Tosolini M, Kirilovsky A, et al,. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol 2011; 29: 610-8.
50. Boland CR, Thibodeau SN, Hamilton SR, et al,. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998; 58: 5248-57.
51. Alexander J, Watanabe T, Wu TT, Rashid A, Li S, Hamilton SR,. Histopathological identification of colon cancer with microsatellite instability. Am J Pathol 2001; 158: 527-35.
52. Smyrk TC, Watson P, Kaul K, Lynch HT,. Tumor-infiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinoma. Cancer 2001; 91: 2417-22.
53. Buckowitz A, Knaebel HP, Benner A, et al,. Microsatellite instability in colorectal cancer is associated with local lymphocyte infiltration and low frequency of distant metastases. Br J Cancer 2005; 92: 1746-53.
54. Ribic CM, Sargent DJ, Moore MJ, et al,. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Eng J Med 2003; 349: 247-57.
55. Linnebacher M, Gebert J, Rudy W, et al,. Frameshift peptide-derived T-cell epitopes: a source of novel tumor-specific antigens. Int J Cancer 2001; 93: 6-11.
56. Dolcetti R, Viel A, Doglioni C, et al,. High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability. Am J Pathol 1999; 154: 1805-13.
57. Guidoboni M, Gafa R, Viel A, et al,. Microsatellite instability and high content of activated cytotoxic lymphocytes identify colon cancer patients with a favorable prognosis. Am J Pathol 2001; 159: 297-304.
58. Michel S, Benner A, Tariverdian M, et al,. High density of FOXP3-positive T cells infiltrating colorectal cancers with microsatellite instability. Br J Cancer 2008; 99: 1867-73.
59. Frey DM, Droeser RA, Viehl CT, et al,. High frequency of tumor-infiltrating FOXP3(+) regulatory T cells predicts improved survival in mismatch repair-proficient colorectal cancer patients. Int J Cancer 2010; 126: 2635-43.
60. Zitvogel L, Kepp O, Kroemer G,. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol 2011; 8: 151-60.
61. Obeid M, Tesniere A, Ghiringhelli F, et al,. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007; 13: 54-61.
62. Apetoh L, Ghiringhelli F, Tesniere A, et al,. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007; 13: 1050-9.
63. Tesniere A, Schlemmer F, Boige V, et al,. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 2010; 29: 482-91.
64. Michaud M, Martins I, Sukkurwala AQ, et al,. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 2011; 334: 1573-7.
65. Martin F, Apetoh L, Ghiringhelli F,. Role of myeloid-derived suppressor cells in tumor immunotherapy. Immunotherapy 2012; 4: 43-57.
66. Ding ZC, Zhou G,. Cytotoxic chemotherapy and CD4+ effector T cells: an emerging alliance for durable antitumor effects. Clin Dev Immunol 2012; 2012: 890178.
67. Yang X, Zhang X, Mortenson ED, Radkevich-Brown O, Wang Y, Fu YX,. Cetuximab-mediated tumor regression depends on innate and adaptive immune responses. Mol Ther 2013; 21: 91-100.
68. Mellor JD, Brown MP, Irving HR, Zalcberg JR, Dobrovic A,. A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer. J Hematol Oncol 2013; 6: 1.
69. Kantoff PW, Higano CS, Shore ND, et al,. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Eng J Med 2010; 363: 411-22.
70. Ellebaek E, Andersen MH, Svane IM, Straten PT,. Immunotherapy for metastatic colorectal cancer: present status and new options. Scand J Gastroenterol 2012; 47: 315-24.
71. Palucka K, Banchereau J,. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012; 12: 265-77.
72. Moulton HM, Yoshihara PH, Mason DH, Iversen PL, Triozzi PL,. Active specific immunotherapy with a beta-human chorionic gonadotropin peptide vaccine in patients with metastatic colorectal cancer: antibody response is associated with improved survival. Clin Cancer Res 2002; 8: 2044-51.
73. Correale P, Cusi MG, Tsang KY, et al,. Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients. J Clin Oncol 2005; 23: 8950-8.
74. Correale P, Rotundo MS, Del Vecchio MT, et al,. Regulatory (FoxP3T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy. J Immunother 2010; 33: 435-41.
75. Correale P, Tagliaferri P, Fioravanti A, et al,. Immunity feedback and clinical outcome in colon cancer patients undergoing chemoimmunotherapy with gemcitabine + FOLFOX followed by subcutaneous granulocyte macrophage colony-stimulating factor and aldesleukin (GOLFIG-1 Trial). Clin Cancer Res 2008; 14: 4192-9.
76. Harris JE, Ryan L, Hoover HC Jr, et al,. Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283. J Clin Oncol 2000; 18: 148-57.
77. Harrop R, Drury N, Shingler W, et al,. Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses. Cancer Immunol Immunother 2008; 57: 977-86.
78. Hoover HC Jr, Brandhorst JS, Peters LC, et al,. Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial. J Clin Oncol 1993; 11: 390-9.
79. Karlsson M, Marits P, Dahl K, et al,. Pilot study of sentinel-node-based adoptive immunotherapy in advanced colorectal cancer. Ann Surg Oncol 2010; 17: 1747-57.
80. Kavanagh B, Ko A, Venook A, et al,. Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides. J Immunother 2007; 30: 762-72.
81. Martins I, Kepp O, Schlemmer F, et al,. Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress. Oncogene 2011; 30: 1147-58.
82. Morse MA, Nair SK, Mosca PJ, et al,. Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNA. Cancer Invest 2003; 21: 341-9.
83. Posner MC, Niedzwiecki D, Venook AP, et al,. A phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases: cancer and leukemia group B study 89903. Ann Surg Oncol 2008; 15: 158-64.
84. Schlag P, Manasterski M, Gerneth T, et al,. Active specific immunotherapy with Newcastle-disease-virus-modified autologous tumor cells following resection of liver metastases in colorectal cancer. First evaluation of clinical response of a phase II-trial. Cancer Immunol Immunother 1992; 35: 325-30.
85. Schulze T, Kemmner W, Weitz J, Wernecke KD, Schirrmacher V, Schlag PM,. Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: results of a prospective randomized trial. Cancer Immunol Immunother 2009; 58: 61-9.
86. Toubaji A, Achtar M, Provenzano M, et al,. Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers. Cancer Immunol Immunother 2008; 57: 1413-20.
87. Vermorken JB, Claessen AM, van Tinteren H, et al,. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet 1999; 353: 345-50.
88. Mazzolini G, Murillo O, Atorrasagasti C, et al,. Immunotherapy and immunoescape in colorectal cancer. World J Gastroenterol 2007; 13: 5822-31.